EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Ferroptosis inhibitors: latest advances and therapeutic potential for pulmonary arterial hypertension

Wenhua Tan, Yuanbo Hu, Liqing Hu, Zhuo Chen, Qianbin Li

Drug Discovery Today · 2026-05 · 31 (3) · 104635

DOI: 10.1016/j.drudis.2026.104635 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Drug Discovery Today, 2026-05. Verfasst von Wenhua Tan und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicinal Chemistry, Xiangya School of Pharmaceutical Sciences, Central South University, Changsha, Hunan 410013, China; Hunan Key Labo…. Hauptthemen laut MEDLINE: Ferroptosis, Pulmonary Arterial Hypertension. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 158 Literaturangaben. Gefördert von: National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Pulmonary arterial hypertension (PAH) is a progressive, high-mortality disease with multifactorial pathology. Although current therapies primarily target vascular remodeling, single-pathway approaches often remain insufficient against its complex pathogenesis. Ferroptosis, an iron-dependent lipid peroxidation-driven cell death, is intrinsically linked to core PAH features, such as oxidative stress, endothelial dysfunction, and inflammation. Therefore, inhibiting ferroptosis presents a promising therapeutic strategy by simultaneously counteracting these key pathological drivers. Here, we provide a detailed review of the latest research progress on ferroptosis inhibitors, elucidate their molecular mechanisms in PAH, highlight their pathogenic significance, and discuss the associated challenges and opportunities, providing insights for novel PAH treatment development.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

FerroptosisPulmonary Arterial HypertensionHumansAnimalsOxidative StressInflammationLipid PeroxidationHypertension, Pulmonary

Stichwörter der Autor:innen

ferroptosis inhibitorsinflammationpulmonary arterial hypertension

Autor:innen und Institutionen

  • Department of Medicinal Chemistry, Xiangya School of Pharmaceutical Sciences, Central South University, Changsha, Hunan 410013, China; Hunan Key Laboratory of Diagnostic and Therapeutic Drug Research for Chronic Disease…
  • Key Laboratory of Study and Discovery of Small Targeted Molecules of Hunan Province, Department of Pharmacy, School of Medicine, Hunan Normal University, Changsha, Hunan 410013, China.

Förderung

  • National Natural Science Foundation of China

Zitieren

APA

Tan, W., Hu, Y., Hu, L., Chen, Z., & Li, Q. (2026). Ferroptosis inhibitors: latest advances and therapeutic potential for pulmonary arterial hypertension. Drug Discovery Today, 31(3), 104635. https://doi.org/10.1016/j.drudis.2026.104635

Vancouver

Tan W, Hu Y, Hu L, Chen Z, Li Q. Ferroptosis inhibitors: latest advances and therapeutic potential for pulmonary arterial hypertension. Drug Discovery Today. 2026;31(3):104635. doi:10.1016/j.drudis.2026.104635

BibTeX
@article{Tan2026,
  author = {Tan, Wenhua and Hu, Yuanbo and Hu, Liqing and Chen, Zhuo and Li, Qianbin},
  title = {Ferroptosis inhibitors: latest advances and therapeutic potential for pulmonary arterial hypertension},
  journal = {Drug Discovery Today},
  year = {2026},
  volume = {31},
  number = {3},
  pages = {104635},
  doi = {10.1016/j.drudis.2026.104635}
}
Kostenlos starten →